The BRB Preclinical
is an NCI-sponsored facility containing bulk cytokines, monoclonal
antibodies, reference standards, and other research reagents that are maintained
under carefully controlled storage conditions. The purpose of this facility is to
maintain and distribute a constant and uniform supply of high quality reagents for
peer-reviewed scientists at non-profit institutions and specific materials to commercial
SHIPPING INFORMATION FOR BRB PRECLINICAL REPOSITORY
Shipping costs are the responsibility of the recipient. Investigators at
not-for-profit institutions within the USA will not be charged a handling
and packaging fee. Due to funding constraints, we must charge a HANDLING AND PACKAGING
FEE for shipments outside the USA and to investigators at commercial establishments.
Once you have placed your order, you will be contacted to arrange payment of the
fee. Fed Ex, UPS or DHL account numbers or if required by recipient’s institution,
a PDF of shipping label(s) are accepted.
The BRB is developing clinical and non-clinical supplies of some of the immunomodulating
agents prioritized in the 2007 Immunotherapy Agent Workshop. Agents such as Ad-CCL21,
IL-7, IL-12, IL-15 and MPL will be made available to the community, through a variety
of standard mechanisms.
Limited amounts of the ch14.18 monoclonal antibody currently in Phase III clinical
trials for neuroblastoma are available for investigators interested in identifying
additional disease indications for this antibody. The antibody produced from SP2/0
hybridoma cells targets the disialoganglioside (GD2). Ch14.18 is suitable for use
in ADCC or other assays requiring a humanized antibody. A murine version of the
antibody (14.18G2a) is also available for immunohistochemistry studies. Hu 14.18-IL2
is available from the repository under the Other Reagents category. The 1A7 anti-idiotype
antibody that recognizes GD2 antibodies will also be available from the repository
after June 1, 2011.
For current development status and information on how to obtain one of these special
agents, please contact
Dr. Karen Muszynski.